NuCana (NASDAQ:NCNA) Shares Down 2.7% – Here’s Why

NuCana PLC Sponsored ADR (NASDAQ:NCNA) fell 2.7% on Monday . The company traded as low as $3.62 and last traded at $3.62. 35,344 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 63,000 shares. The stock had previously closed at $3.72.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NCNA shares. Wall Street Zen raised NuCana from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

NuCana Trading Down 3.7%

The company has a market capitalization of $102,900.00, a P/E ratio of -0.02 and a beta of 1.59. The firm’s 50 day moving average price is $4.11 and its two-hundred day moving average price is $7.40.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($2.69) by $2.59. Analysts anticipate that NuCana PLC Sponsored ADR will post -13.42 earnings per share for the current fiscal year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.